Skip to main content
Equibles
VBIO logo

VBIO · Valion Bio, Inc.

Track VBIO — free

Use VBIO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about VBIO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.13 +0.01 (+7.67%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company’s current cash levels and burn rate, amongst other things, the Company believes its cash and financial resources may be insufficient to meet the Company’s anticipated needs for the twelve months following the date of issuance of the financial statements for the six months ended June 30, 2026, included elsewhere in this Report, which raises substantial doubt about the Company’s ability to continue as a going concern within one year from the issuance date of the financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$3.46M
Shares
22.19M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.12 Open$0.15 Day$0.12–0.16 52W close$0.12–3.15 Avg vol 30d18.1M Short int1.6M · 7.4% float · 1.0d Short vol44% Last earningsMay 14, 2026 DataMar 2025–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Mar 7, 2025; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −88%
      below
      Price vs 50-day avg −66%
      below
      RSI (14) 29
      oversold
      MACD trend Positive
      52-week position 0%
      near low
      Volume (OBV) Bullish div.
      accumulating
      Momentum
      relative strength
      Very Weak
      1-month return −56%
      trailing
      6-month return −86%
      trailing
      YTD return −92%
      this year
      Relative strength −100%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $0 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      +44% holders QoQ · +5 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      7.42% of float · ▲ +96.5% MoM · 1.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      13 holders — near 1-yr high, broad support
      Squeeze score 68
      elevated · 0–100
      Fundamentals
      Weak
      Revenue growth −34%
      Y/Y
      Gross margin 0%
      contracting
      EPS growth +89%
      Y/Y
      Free cash flow $-7.0M
      Balance sheet $12.6M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 121%
      annualized · 1-yr
      Max drawdown −96%
      past year
      ATR 70.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Prior guidance period ended · from the 8-K filed Nov 14, 2025
      Additional related expenditures · through the end of the year $20,000 – $50,000

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      3 · 2 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −88% Bearish
      Price vs 50-day avg
      −66% Bearish
      RSI (14)
      29 Neutral
      MACD trend
      Positive Bullish
      52-week position
      0% Bearish
      Volume (OBV)
      Bullish div. Bullish
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $0 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      +44% holders QoQ · +5 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      7.42% of float · ▲ +96.5% MoM · 1.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      13 holders — near 1-yr high, broad support
      Price context
      position in its 52-week range
      Range low $0 Now $0 · 0% Range high $3
      vs 200-day avg -88% vs 50-day avg -66%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      VBIO
      Valion Bio, Inc.
      this stock
      		$3.46M -91.5% -33.7% — 7.4%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.72B +20.8% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $83.89B +4.6% +20.8% 20.2 2.3%
      ARGX
      Argenx SE
      		 $65.12B +25.9% — — 1.9%
      CSLLY
      Csl Ltd
      		 $59.92B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      13
      % held
      1.8%
      Net QoQ
      +133.9K sh
      Top holder
      Murchinson Ltd.
      Held Float
      View
      Held by Funds
      Fund positions
      2
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      1.6M
      Days to cover
      1.0d
      Change
      +808.4K sh
      View
      Short Volume
      Short vol %
      44%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      78.2K
      Value
      $21.9K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      63.3%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $780.0K
      Net income (FY)
      $-8.9M
      EPS diluted
      $-19.68
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 27, 2026
      This year
      24
      View
      Exempt Offerings
      Offering
      $16.3M
      Filed
      Dec 29, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 14, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Mar 7, 2025; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      VBIO +0.4% -55.9% -85.6% -60.5% -91.5%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY -0.7% -59.9% -100.3% -63.7% -104.6%
      Key facts CIK 1787740 CUSIP 888705308 13F (30d) 15 filings 12 filers Visit website

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)